Perbandingan Kinerja Keuangan Perusahaan Farmasi Milik BUMN dan Swasta di BEI Periode 2016-2018

The purpose of this study was to determine the comparison of the financial performance of state-owned pharmaceutical companies with private-owned pharmaceutical companies and find out what factors affect differences in company performance based on analysis of profitability, market value rations and...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Lia Candrayani, Ziana Fitri, Kharis Fadlullah Hana
Formato:	article
Lenguaje:	EN ID
Publicado:	Fakultas Ekonomi dan Bisnis Islam 2020
Materias:	financial performance roe eps eva Business HF5001-6182 Banking HG1501-3550
Acceso en línea:	https://doaj.org/article/f032e75cc3c641509f4b0605697c4cc5
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f032e75cc3c641509f4b0605697c4cc5
record_format	dspace
spelling	oai:doaj.org-article:f032e75cc3c641509f4b0605697c4cc52021-11-22T10:14:15ZPerbandingan Kinerja Keuangan Perusahaan Farmasi Milik BUMN dan Swasta di BEI Periode 2016-20182714-55652714-779710.24090/mabsya.v2i1.3877https://doaj.org/article/f032e75cc3c641509f4b0605697c4cc52020-06-01T00:00:00Zhttp://ejournal.uinsaizu.ac.id/index.php/mabsya/article/view/3877https://doaj.org/toc/2714-5565https://doaj.org/toc/2714-7797The purpose of this study was to determine the comparison of the financial performance of state-owned pharmaceutical companies with private-owned pharmaceutical companies and find out what factors affect differences in company performance based on analysis of profitability, market value rations and EVA. This study using a quantitative approach using a comparative descriptive method that took a sample of 4 pharmaceutical companies listed on the Stock Excahange. The data analysis technique uses a different independent sample T-test by comparing financial data from state-owned and private pharmaceutical companies in the 2016-2018 period. The results of the study show that return on equity (ROE) analysis of state-owned pharmaceutical companies is not safe because there are significant differences in the precentage above 15% and private pharmaceutical above 15%. The earning per share (EPS) analysis results of state-owned companies reached 0,35 and private pharmaceutical companies reached 50,71. As well as economic value added (EVA) analysis produces data there are differences in financial performace where the state-owned pharmaceutical companies have increased and privat pharmaceutical companies have decreased.Lia CandrayaniZiana FitriKharis Fadlullah HanaFakultas Ekonomi dan Bisnis Islamarticlefinancial performanceroeepsevaBusinessHF5001-6182BankingHG1501-3550ENIDMabsya, Vol 2, Iss 1, Pp 19-34 (2020)
institution	DOAJ
collection	DOAJ
language	EN ID
topic	financial performance roe eps eva Business HF5001-6182 Banking HG1501-3550
spellingShingle	financial performance roe eps eva Business HF5001-6182 Banking HG1501-3550 Lia Candrayani Ziana Fitri Kharis Fadlullah Hana Perbandingan Kinerja Keuangan Perusahaan Farmasi Milik BUMN dan Swasta di BEI Periode 2016-2018
description	The purpose of this study was to determine the comparison of the financial performance of state-owned pharmaceutical companies with private-owned pharmaceutical companies and find out what factors affect differences in company performance based on analysis of profitability, market value rations and EVA. This study using a quantitative approach using a comparative descriptive method that took a sample of 4 pharmaceutical companies listed on the Stock Excahange. The data analysis technique uses a different independent sample T-test by comparing financial data from state-owned and private pharmaceutical companies in the 2016-2018 period. The results of the study show that return on equity (ROE) analysis of state-owned pharmaceutical companies is not safe because there are significant differences in the precentage above 15% and private pharmaceutical above 15%. The earning per share (EPS) analysis results of state-owned companies reached 0,35 and private pharmaceutical companies reached 50,71. As well as economic value added (EVA) analysis produces data there are differences in financial performace where the state-owned pharmaceutical companies have increased and privat pharmaceutical companies have decreased.
format	article
author	Lia Candrayani Ziana Fitri Kharis Fadlullah Hana
author_facet	Lia Candrayani Ziana Fitri Kharis Fadlullah Hana
author_sort	Lia Candrayani
title	Perbandingan Kinerja Keuangan Perusahaan Farmasi Milik BUMN dan Swasta di BEI Periode 2016-2018
title_short	Perbandingan Kinerja Keuangan Perusahaan Farmasi Milik BUMN dan Swasta di BEI Periode 2016-2018
title_full	Perbandingan Kinerja Keuangan Perusahaan Farmasi Milik BUMN dan Swasta di BEI Periode 2016-2018
title_fullStr	Perbandingan Kinerja Keuangan Perusahaan Farmasi Milik BUMN dan Swasta di BEI Periode 2016-2018
title_full_unstemmed	Perbandingan Kinerja Keuangan Perusahaan Farmasi Milik BUMN dan Swasta di BEI Periode 2016-2018
title_sort	perbandingan kinerja keuangan perusahaan farmasi milik bumn dan swasta di bei periode 2016-2018
publisher	Fakultas Ekonomi dan Bisnis Islam
publishDate	2020
url	https://doaj.org/article/f032e75cc3c641509f4b0605697c4cc5
work_keys_str_mv	AT liacandrayani perbandingankinerjakeuanganperusahaanfarmasimilikbumndanswastadibeiperiode20162018 AT zianafitri perbandingankinerjakeuanganperusahaanfarmasimilikbumndanswastadibeiperiode20162018 AT kharisfadlullahhana perbandingankinerjakeuanganperusahaanfarmasimilikbumndanswastadibeiperiode20162018
_version_	1718417769864626176

Perbandingan Kinerja Keuangan Perusahaan Farmasi Milik BUMN dan Swasta di BEI Periode 2016-2018

Ejemplares similares